“Working at GTP over the past years amongst some of the gene therapy pioneers has been tremendously rewarding. It is a collaborative and science-driven environment, and I am proud to help develop next-generation safe gene therapy treatments for underserved patients who suffer from devastating genetic diseases.”
Juliette Hordeaux has 13 years of experience in AAV-mediated gene therapy and translational research. She has a French Veterinary Medical Degree, has been European board certified in Veterinary Pathology since 2011, and received her PhD from the University of Nantes. She has been working at the University of Pennsylvania’s Gene Therapy Program (GTP) for seven years where she has led or co-led five programs through successful IND applications. Juliette currently oversees the neurology and cardiology portfolios, as well as investigative toxicology and histopathology. She leads a team of research directors, investigators, and specialists developing cutting-edge AAV gene therapies and working with internal core facilities and external Industry partners to collect quality and focused preclinical data. Her team also investigates AAV-mediated toxicity and ways to develop safer gene therapy modalities. Juliette leads the GTP Histopathology Core that supports research and discovery activities as well as GLP-compliant toxicology studies. She authored or co-authored over 20 peer-reviewed articles, is a co-inventor on several patent applications, and is a regular invited speaker in events discussing AAV-mediated toxicity.
Learn more about our staff and scientists.